Drugs / PRGN-2012
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04724980 | Mar 2021 → Jun 2024 overdue | human papilloma virus infection, recurrent respiratory papillomatosis | Precigen, Inc | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRGN-2012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04724980 ↗ |